Vessi Medical Closes $16.5 Million Series A Round for Innovative Cryotherapy Bladder Cancer Treatment

February 14, 2024

Investors include an undisclosed global strategic investor, ALIVE VC and Agriline

MISGAV, Israel, Feb. 14, 2024 /PRNewswire/ — Vessi Medical Ltd. (“Vessi”) announced today that it has closed a Series A financing round of $16.5 million for its cryotherapy technology to treat Non Muscle Invasive Bladder Cancer (“NMIBC”). Leading investors in the round are an undisclosed global strategic investor, ALIVE- Israel HealthTech Fund, and Agriline, a trust of which UK investor Vincent Tchenguiz is a discretionary beneficiary, joining The Trendlines Group.

Read more at prnewswire.com

Related news for (TRNLY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.